DK0901374T3 - Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser - Google Patents

Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser

Info

Publication number
DK0901374T3
DK0901374T3 DK97926590T DK97926590T DK0901374T3 DK 0901374 T3 DK0901374 T3 DK 0901374T3 DK 97926590 T DK97926590 T DK 97926590T DK 97926590 T DK97926590 T DK 97926590T DK 0901374 T3 DK0901374 T3 DK 0901374T3
Authority
DK
Denmark
Prior art keywords
neurological disorders
tetrahydropteridines
pyridylpiperazines
treatment
crf
Prior art date
Application number
DK97926590T
Other languages
Danish (da)
English (en)
Inventor
Richard Gerald Wilde
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of DK0901374T3 publication Critical patent/DK0901374T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK97926590T 1996-05-23 1997-05-19 Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser DK0901374T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1819896P 1996-05-23 1996-05-23
PCT/US1997/008448 WO1997044038A1 (en) 1996-05-23 1997-05-19 Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders

Publications (1)

Publication Number Publication Date
DK0901374T3 true DK0901374T3 (da) 2004-04-05

Family

ID=21786748

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97926590T DK0901374T3 (da) 1996-05-23 1997-05-19 Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser

Country Status (14)

Country Link
US (3) US6083948A (de)
EP (1) EP0901374B1 (de)
JP (1) JP2000511183A (de)
AT (1) ATE255896T1 (de)
AU (1) AU739269B2 (de)
CA (1) CA2255650A1 (de)
DE (1) DE69726724T2 (de)
DK (1) DK0901374T3 (de)
ES (1) ES2213216T3 (de)
IL (1) IL127170A0 (de)
NZ (1) NZ332704A (de)
PT (1) PT901374E (de)
WO (1) WO1997044038A1 (de)
ZA (1) ZA973884B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531475B1 (en) * 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
ES2180338T3 (es) 1998-11-12 2003-02-01 Neurocrine Biosciences Inc Antagonistas del receptor de crf y metodos relacionados.
DK1129096T3 (da) * 1998-11-12 2003-09-15 Neurocrine Biosciences Inc CRF-receptorantagonister og fremgangsmåder, der er relateret dertil
EP1040831A3 (de) * 1999-04-02 2003-05-02 Pfizer Products Inc. Verwendung von Corticotropin Releasing Factor (CRF) Antagonisten zur Prophylaxe des plötzlichen Todes
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
OA12050A (en) * 1999-09-30 2006-05-02 Neurogen Corp Certain alkylene diamine-substituted heterocycles.
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
WO2001083486A1 (en) * 2000-05-01 2001-11-08 Bristol-Myers Squibb Pharma Company Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
US6440960B1 (en) 2000-05-18 2002-08-27 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
WO2002005749A2 (en) * 2000-07-19 2002-01-24 Bristol-Myers Squibb Pharma Company Crf2 ligands in combination therapy
EP2404603A1 (de) * 2000-10-23 2012-01-11 Glaxosmithkline LLC Neue trisubstitutierte 8H-Pyrido[2,3-d]pyrimidin-7-Onderivate zur Behandlung von durch CSBP/p38kinase vermittelten Krankheiten
AU2002249474B2 (en) 2001-04-30 2006-01-12 Glaxo Group Limited Crf receptor antagonists
DE60215637T2 (de) 2001-05-21 2007-08-23 Neurocrine Biosciences, Inc., San Diego Tri- und tetraaza-acenaphthylen-derivate als crf-rezeptor-antagonisten
MXPA04010267A (es) * 2002-04-19 2005-02-03 Smithkline Beecham Corp Compuestos novedosos.
US7067658B2 (en) * 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
EP1846410B1 (de) * 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydrochinazolinone als 5ht-modulatoren
CA2614223A1 (en) * 2005-02-24 2006-08-31 Dr Pharma Nova, Llc A registry method and control system for dea schedule ii-v medicines
US20090137550A1 (en) * 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
PE20061351A1 (es) 2005-03-25 2007-01-14 Glaxo Group Ltd COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
EP1865959A2 (de) * 2005-03-25 2007-12-19 Glaxo Group Limited Verfahren zur herstellung von pyrido¦2,3-d pyrimidin-7-on and 3,4-dihydropyrimido¦4,5-d pyrimidin-2(1h)-on-derivaten
TW200724142A (en) * 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
JP2009502959A (ja) * 2005-07-28 2009-01-29 ブリストル−マイヤーズ スクイブ カンパニー セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−１ｈ−ピリド［４，３，ｂ］インドール
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
TW200808805A (en) 2006-04-12 2008-02-16 Vertex Pharma Tetrahydropteridines useful as inhibitors of protein kinases
CN101479269A (zh) * 2006-06-23 2009-07-08 阿斯利康(瑞典)有限公司 蝶啶衍生物及其作为组织蛋白酶抑制剂的用途
SI2266990T1 (sl) 2008-04-15 2013-01-31 Eisai R&D Management Co. Ltd. Spojina 3-fenilpirazolo(5,1-b)tiazola
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
WO2010096426A2 (en) * 2009-02-20 2010-08-26 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
ES2661850T3 (es) 2009-09-14 2018-04-04 Gilead Sciences, Inc. Moduladores de receptores del tipo toll
NZ599342A (en) 2009-09-25 2014-04-30 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
SG179206A1 (en) 2009-09-25 2012-04-27 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
CN103052677B (zh) 2010-06-10 2016-03-16 联合碳化化学及塑料技术有限责任公司 硫代双酚抗氧化剂/聚乙二醇共混物
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CA2836272C (en) 2011-05-20 2019-09-24 Union Carbide Chemicals & Plastics Technology Llc Thiobis phenolic antioxidant/polyethylene glycol blends
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
CR20170076A (es) 2014-08-04 2017-06-26 Nuevolution As Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
JP2017526730A (ja) 2014-09-16 2017-09-14 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体モジュレーターの固体形態
US9573952B2 (en) 2014-09-16 2017-02-21 Gilead Sciences, Inc. Methods of preparing toll-like receptor modulators
WO2017014323A1 (en) 2015-07-23 2017-01-26 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
WO2017056115A1 (en) * 2015-10-03 2017-04-06 Sun Pharma Advanced Research Company Limited Novel n-aryl containing fused heterocyclic compounds
EP3377493B1 (de) 2015-11-20 2020-04-08 Forma Therapeutics, Inc. Purinone als ubiquitinspezifische protease-1-inhibitoren
KR20220011685A (ko) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Tlr7 조절 화합물과 hiv 백신의 조합
AU2020408107B2 (en) 2019-12-20 2026-04-23 Nuevolution A/S Compounds active towards nuclear receptors
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
EP4126874A1 (de) 2020-03-31 2023-02-08 Nuevolution A/S Gegen nukleare rezeptoren aktive verbindungen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3127402A (en) * 1964-03-31 Y-oxopteridine derivatives
US4077955A (en) * 1977-02-17 1978-03-07 E. R. Squibb & Sons, Inc. Amino derivatives of 1,2,3,4-tetrahydro-2-oxopyrido[2,2-b]-pyrazine carboxylic acids and esters
EP0008864A1 (de) * 1978-08-15 1980-03-19 FISONS plc Pyridopyrazin- und Chinoxalinderivate, Verfahren zu ihrer Herstellung, und sie enthaltende pharmazeutische Zusammensetzungen
EP0074929A1 (de) * 1981-09-16 1983-03-23 Ciba-Geigy Ag Neue polycyclische Polyazaheterocyclen, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
US4510141A (en) * 1982-09-13 1985-04-09 Ciba-Geigy Corporation Tricyclic polyazaheterocycles for treating depression or anxiety
GB8318833D0 (en) * 1983-07-12 1983-08-10 Wellcome Found Chemical compounds
JPS5976086A (ja) * 1982-09-20 1984-04-28 ザ　ウエルカム　フアウンデ−シヨン　リミテツド プテリジン化合物
ATE194985T1 (de) 1990-11-06 2000-08-15 Yamanouchi Pharma Co Ltd Kondensiertes pyrazinderivat
US5198547A (en) * 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
TW274550B (de) * 1992-09-26 1996-04-21 Hoechst Ag
KR100263429B1 (ko) * 1994-06-06 2000-08-01 디. 제이. 우드 코르티코트로핀-방출 인자(crf) 길항 활성을 갖는 치환된 피라졸
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
EP0765327B1 (de) 1994-06-16 1999-07-21 Pfizer Inc. Pyrazolo und pyrrolopyridine
JP3273108B2 (ja) * 1994-09-21 2002-04-08 アサヒビール株式会社 新規ピリド〔２，３−ｄ〕ピリミジン誘導体及びその製造方法

Also Published As

Publication number Publication date
ATE255896T1 (de) 2003-12-15
WO1997044038A1 (en) 1997-11-27
JP2000511183A (ja) 2000-08-29
US20030064993A1 (en) 2003-04-03
EP0901374A1 (de) 1999-03-17
DE69726724T2 (de) 2004-12-09
ES2213216T3 (es) 2004-08-16
PT901374E (pt) 2004-04-30
US6083948A (en) 2000-07-04
AU3131697A (en) 1997-12-09
NZ332704A (en) 2000-05-26
CA2255650A1 (en) 1997-11-27
US6399609B1 (en) 2002-06-04
ZA973884B (en) 1998-11-06
US6869955B2 (en) 2005-03-22
IL127170A0 (en) 1999-09-22
EP0901374A4 (de) 2001-05-09
EP0901374B1 (de) 2003-12-10
DE69726724D1 (de) 2004-01-22
AU739269B2 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
PT901374E (pt) Tetra-hidropteridinas e piridilpiperazinas para o tratamento de disturbios neurologicos
LV12262A (lv) Ar arilaminu kondenseti piridini un pirimidini
BR9307646A (pt) Pirrolopirimidinas como antagonistas de crf
DK1344779T3 (da) Azolo-pyrimidiner
MXPA03010324A (es) PIRAZINONAS, PIRIDINAS Y PIRIMIDINAS SUBSTITUIDAS COMO LIGANDOS DEL FACTOR DE LIBERACIoN DE CORTICOTROPINA.
LV12292A (lv) Triazinu un pirimidinu azoloatvasinajumi
DE69425267D1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
NZ335992A (en) Substituted pyrimidinone and pyridone compounds and methods of use
DK0788513T3 (da) Anvendelse af bindingsmidler for CD23 i behandlingen af atoimmune sygdomme
DK0786991T3 (da) Polyaminforbindelsre til behandling af proliferative karsygdomme
NO20006699D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
DK1017377T3 (da) Anvendelse af 6,7-substituerede 2-aminotetraliner til behandling af af cytokin fremkaldte inflammatoriske tilstande